Feasibility of an intensified myeloablative conditioning regimen consisting of busulfan, fludarabine, cytarabine, and total body irradiation before single cord blood transplantation in elderly patients

Int J Hematol. 2021 Jul;114(1):85-93. doi: 10.1007/s12185-021-03131-9. Epub 2021 Mar 19.

Abstract

The optimal conditioning regimen for stem cell transplantation in elderly patients remains to be established. We developed a novel preparative regimen using fludarabine 180 mg/m2, intravenous busulfan 12.8 mg/m2, cytarabine 8 g/m2, and 4-Gy total body irradiation before cord blood transplantation (CBT) in patients older than 55 years with various hematological malignancies. All but one patient received graft-versus-host disease (GVHD) prophylaxis consisting of cyclosporine (CsA) and short-term methotrexate (sMTX). Thirty-three patients were included in this study, with a median age of 64 years (range 56-70). The disease risk index was high or very high in 67% of patients, and 73% had a disease status other than complete remission. The probabilities of overall survival and disease-free survival at 3 years were 60 and 57%, respectively. The cumulative incidences of relapse and non-relapse mortality at 3 years were 18 and 25%, respectively. Regimen-related toxicities were generally tolerable. Disease-free survivors (n = 20) stopped immunosuppressants at a median of 7.4 months (range 2.6-25.0), in all cases by the time of the last follow-up. In conclusion, this highly myeloablative conditioning regimen resulted in a high probability of disease-free, GVHD-free, immunosuppressant-free survival after single CBT.(190 words).

Keywords: Cord blood transplantation; Elderly; Myeloablative conditioning.

MeSH terms

  • Aged
  • Busulfan / therapeutic use*
  • Cytarabine / therapeutic use*
  • Female
  • Fetal Blood / transplantation*
  • Graft vs Host Disease / prevention & control
  • Humans
  • Male
  • Middle Aged
  • Myeloablative Agonists / therapeutic use*
  • Transplantation Conditioning / methods
  • Treatment Outcome
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use
  • Whole-Body Irradiation

Substances

  • Myeloablative Agonists
  • Cytarabine
  • Vidarabine
  • Busulfan
  • fludarabine